Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Intrauterine lavage therapy
The First People's Hospital of Lianyungang
Intrauterine Adhesions
1 trial -
Intravenous Anesthetic Induction with Ciprofol for Painless Colonoscopy in Elderly Patients
The First People's Hospital of Lianyungang
Ciprofol
1 trial -
Irinotecan Hydrochloride Liposome Injection；Carboplatin Injection；Serplulimab Injection
The First People's Hospital of Lianyungang
Small Cell Lung Cancer
1 trial -
Iron sucrose, Human Erythropoietin Injection, Vitamin C
The First People's Hospital of Lianyungang
Anemia
1 trial -
Itraconazole
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Sporotrichosis
1 trial -
Ivarmacitinib tablet
The First People's Hospital of Lianyungang
Polymyalgia Rheumatics (PMR)
1 trial -
Ixekizumab+Jueyin Granules
Universal Integrated
Plaque Psoriasis
1 trial -
Jianpixiaozhong particles and Wuse Dietotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Idiopathic Membranous Nephropathy
1 trial -
KL003 Cell Injection
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Sickle Cell Disease
1 trial -
Kava (Piper methysticum) extract
The First People's Hospital of Lianyungang
Sleep
1 trial -
Ketamine
The First People's Hospital of Lianyungang
Intensive Care Unit
1 trial -
Ketogenic diet
Hospital Authority, Hong Kong
Drug Resistant Epilepsy
1 trial -
Kunxian capsule
The First People's Hospital of Lianyungang
Diabetic Nephropathy
1 trial -
LCAR- F33S cells intravenous infusion
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Relapsed/Refractory Multiple Myeloma(MM)
1 trial -
LCAR-M61S cells preparation
Nanjing Legend Biotech Co.
Relapsed/Refractory Multiple Myeloma
1 trial -
Lactated ringers solution
The First People's Hospital of Lianyungang
Pancreatitis, Chronic
1 trial -
Lactobacillus rhamnosus F-1
Biotech Pharmaceutical Co.,
Allergic Rhinitis
1 trial -
Lactulose
The First People's Hospital of Lianyungang
Colon Disease
1 trial -
Latanoprost
The First People's Hospital of Lianyungang
Ocular Hypertension
1 trial -
Learning with 3D-MR visualization models
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Teaching Innovation
1 trial -
Leflunomide
Xiyuan Hospital of China Academy of Chinese Medical Sciences
ANCA Associated Vasculitis
1 trial -
Lenalidomide
The First People's Hospital of Lianyungang
Diffuse Large B Cell Lymphoma
1 trial -
Letrozole
The First People's Hospital of Lianyungang
Intrauterine Insemination
1 trial -
Letrozole
International Peace Maternity and Child Health Hospital
Letrozole
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources